Table 1.
Baseline sociodemographic and clinical characteristics of the study sample.
| Group A (n=6) | Group B (n=6) | p value | |
|---|---|---|---|
| Age (years) | 76.67 ± 5.58 | 76.50 ± 8.94 | 0.970 |
| Gender (male/female) | 5/1 | 5/1 | 1.000 |
| Years of education | 10.17 ± 1.60 | 9.50 ± 0.55 | 0.445 |
| Family status | 0.392 | ||
| Unmarried | 0 | 1 | |
| Married | 3 | 1 | |
| Divorced | 0 | 1 | |
| Widowed | 3 | 3 | |
| Inpatient (months) | 16.50 ± 14.95 | 10.33 ± 5.50 | 0.394 |
| Hoehn & Yahr stage | 0.255 | ||
| 1–1.5 | 0 | 0 | |
| 2–2.5 | 2 | 1 | |
| 3 | 0 | 2 | |
| 4 | 2 | 2 | |
| 5 | 2 | 1 | |
| Months since PD diagnosis | 72.00 ± 37.18 | 74.00 ± 48.84 | 0.938 |
| Months since dementia diagnosis | 26.17 ± 28.20 | 27.67 ± 12.66 | 0.908 |
| LEDD | 290.17 ± 236.60 | 239.67 ± 228.06 | 0.714 |
| CCI | 3.50 ± 3.78 | 2.33 ± 1.03 | 0.937 |
| Number of antidementiva | 0.83 ± 0.98 | 1.00 ± 0.63 | 0.699 |
| Number of antidepressiva | 0.83 ± 1.17 | 0.42 ± 0.66 | 0.699 |
| Number of other medications | 11.11 ± 3.27 | 10.42 ± 2.33 | 0.699 |
| MMSE (max. 30 points) | 17.50 ± 5.75 | 18.17 ± 5.35 | 0.839 |
| CERAD total score (max. 111 points) | 39.17 ± 9.37 | 38.50 ± 13.78 | 0.924 |
| GDS (max. 15 points) | 6.00 ± 2.00 | 8.67 ± 4.46 | 0.394 |
Values are presented as the mean ± standard deviation or frequency. Abbreviations: LEDD, levodopa equivalent daily dose; CCI, Charlson Comorbidity Index; MMSE, Mini-Mental State Examination; CERAD, Consortium to Establish a Registry for Alzheimer's Disease; GDS, Geriatric Depression Scale.